Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of 7% ectoine cream for mild to moderate facial seborrheic dermatitis
TCTR20260521005Phase 3Completed
- Sponsor
- QualiMed Health Network
- Start
- Jun 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ectoin in seborrheic dermatitis (SD), sponsored by QualiMed Health Network. Started Jun 2024; status: completed.
02
Drugs
ectoin
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on TCTR20260521005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260521005.